Changing the course of canine osteoarthritis (OA) treatment…

1 intra-articular injectiondelivers up to1 full year ofromps and runs

running dog
syringe
syringe
Synovetin OA vial

NEW Synovetin OA™ breaks the cycle of inflammation and pain, clinically improving mobility and providing long-lasting relief.

Synovetin OA™ is a novel, conversion electron therapy that targets macrophages and synoviocytes in the injected joint.1,2

icon joint

Provides durable pain and inflammation relief

icon dog

Restores the active lifestyle of dogs with their families

icon change

Alters the course of chronic OA treatment

Synovetin OA vial
reduction in inflammatory mediators

See how the dual cellular targeting of Synovetin OA™ works to deliver targeted treatment.

reduction in inflammatory mediators

Delivers sustained, long-term relief2

Helps you more confidently manage patients

Learn more about extended effectiveness

Answers a significant unmet need

Helps improve your canine patient's quality of life3

Learn more about OA pain and Inflammation

Provides targeted, non-systemic therapy1

Breaks the inflammatory cycle and improves mobility2

Learn more about the safety of targeted OA therapy

References:

  1. Fox SM, Donecker JM. Synovitis Technical Bulletin. Exubrion Therapeutics July 2019.
  2. Data on File, Exubrion Therapeutics.
  3. American College of Veterinary Surgeons. Canine elbow dysplasia. Available at: https://www.acvs.org/small-animal/canine-elbow-dysplasia. Accessed 5/15/19.